Quinolinic acid

MedChemExpress

Cat. No.:	HY-100807	0
CAS No.:	89-00-9	Ī
Molecular Formula:	C ₇ H ₅ NO ₄	
Molecular Weight:	167.12	
Target:	Endogenous Metabolite; iGluR	UL A
Pathway:	Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel; Neuronal Signaling	N Y
Storage:	Powder -20°C 3 years	
	4°C 2 years	0
	In solvent -80°C 6 months	
	-20°C 1 month	

SOLVENT & SOLUBILITY

In Vitro	0,	DMSO : 33.33 mg/mL (199.44 mM; Need ultrasonic) H ₂ O : 3.33 mg/mL (19.93 mM; Need ultrasonic)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	5.9837 mL	29.9186 mL	59.8372 mL		
	Stock Solutions	5 mM	1.1967 mL	5.9837 mL	11.9674 mL		
		10 mM	0.5984 mL	2.9919 mL	5.9837 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					
n Vivo		1. Add each solvent one by one: PBS Solubility: 9.09 mg/mL (54.39 mM); Clear solution; Need ultrasonic and warming and heat to 60°C					
		2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (14.96 mM); Clear solution					
		3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (14.96 mM); Clear solution					
		4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (14.96 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description

Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction^[1]
^[2].

Product Data Sheet

IC ₅₀ & Target	Human Endogenous Metabolite	NMDA Receptor	Microbial Metabolite		
In Vitro	Quinolinic acid (0-50 mM; 24 hours) decreases the percentage of survival cells ranging from 100±0.01% at 5 mM to 45.23±0.01% at 50 mM in N18D3 cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[2]				
		N18D3 cells, hybrid neuronal cell line obtained by fusion of dorsal root ganglions isolated from 4-week-old Balb/C mouse with the mouse neuroblastoma N18TG2 cells			
	Concentration:	0, 10, 20, 30, 40, 50 mM			
	Incubation Time:	24 hours			
	Result:	There was a corresponding decrea 100±0.01% at 5 mM to 45.23±0.01%	ise in the percentage of survival cells ranging from 6 at 50 mM.		

CUSTOMER VALIDATION

- Hepatology. 2022 Jul 11.
- Cell Rep. 2022 Mar 8;38(10):110462.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Heyes MP, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992 Oct;115 (Pt 5):1249-73.

[2]. Jang S, et al. Neuroprotective effects of (-)-epigallocatechin-3-gallate against quinolinic acid-induced excitotoxicity via PI3K pathway and NO inhibition. Brain Res. 2010 Feb 8;1313:25-33.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA